Patient Organisation Cholangiocarcinoma Education Resources

We have created resources for these groups to provide them with the latest, credible information and data on CCA; these documents have been compiled from extensive literature reviews, reviewed independently, and endorsed by CCA experts. The information contained will help advocacy groups to create strong, robust cases/presentations to educate local healthcare authorities on everything from CCA diagnosis and genetic testing to treatments and clinical trials.

Currently, these documents are available in English only; we are working to translate them into French, Italian, German and Spanish to facilitate their use and expand their reach. We are proud to share these with the European CCA community to empower them in their life-changing work.


Introduction to Cholangiocarcinoma

A comprehensive introduction to the signs, symptoms and causes of CCA, followed by details on diagnosis, treatments, targeted therapies, nutrition, clinical trials, and patient perspectives.

To download the CCA Introduction resource in English, click here.

Coming soon: CCA Introduction resource in French, Italian, German and Spanish.

Introduction to Cholangiocarcinoma Powerpoint

An abbreviated PowerPoint version of the Introduction document.

To download the CCA PowerPoint resource in English, click here.

Coming soon: CCA PowerPoint resource in French, Italian, German and Spanish

Introduction to Cholangiocarcinoma Fast Facts

An abbreviated version of the Introduction document, written in a format that enables rapid assimilation of key CCA facts across a range of topics.

To download the CCA Fast Facts resource in English, click here.

Coming soon: CCA Fast Facts resource in French, Italian, German and Spanish.


All resources are endorsed by CCA experts and members of AMMF’s Clinical/Medical Advisory Board: Professor Juan Valle, Professor John Bridgewater, Mr. Hassan Malik, Professor Shahid A. Khan, and Dr. Christopher Wadsworth.

Acknowledgements

These resources have been developed by AMMF with the kind support of AstraZeneca, Incyte, Taiho Oncology, Servier and Jazz Pharmaceuticals. Please note, the supporters had no editorial control over content in the resources.

March 2024